A Phase 3 interventional study of collagenase clostridium histolyticum in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This 12-month study had two phases: a 90-day double-blind, randomized, placebo-controlled phase and a nine-month open-label extension phase. Before treatment, eligible subjects were stratified by the primary joint type (30 metacarpophalangeal [MP] joints and 30 proximal interphalangeal [PIP] joints) and by severity of the primary joint contracture (ie, up to 50° or >50° for MP joints and up to 40° or >40° for PIP joints) and then randomized in a 2:1 ratio to either AA4500 0.58 mg or placebo. Upon completion of the double-blind phase (ie, 90-day evaluation after the first injection), all subjects were eligible to enter the open-label extension phase of the study in which they were followed for an additional nine months. Subjects who required further treatment because they either did not achieve reduction in contracture to 5° or less, the cord affecting the primary joint received placebo, another cord received less than three injections of AA4500, or they had untreated cords that were affecting other joints had the option to receive up to five additional injections of AA4500 0.58 mg in the open-label extension phase, with individual cords receiving up to three injections of AA4500.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 [NCT00528606] and AUX-CC-859 [NCT00533273]) and 7 non-pivotal studies were evaluated.
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: collagenase clostridium histolyticum
Biological: collagenase clostridium histolyticum
Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
Also known as: XIAFLEX®, AA4500
Reduction in Primary Joint Contracture to 5° or Less
Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after last injection
Clinical Improvement in Primary Joint After the Last Injection
Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, Within 30 days after last injection
Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection
Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
Time frame: Baseline, Day 30 after last injection
Change From Baseline Range of Motion in Primary Joint After the Last Injection
Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion
Time frame: Baseline, Day 30 after last injection
Time to Reach Clinical Success in Primary Joint
Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
Time frame: Within 30 days after last injection
Clinical Success in Primary Joint After the First Injection
Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after first injection
Clinical Improvement in Primary Joint After the First Injection
Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, Within 30 days after first injection
Percent Reduction From Baseline Contracture of Primary Joint After the First Injection
Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
Time frame: Baseline, Day 30 after first injection
Change From Baseline Range of Motion in Primary Joint After the First Injection
Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion
Time frame: Baseline, Day 30 after first injection
Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection
Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after last injection
Clinical Improvement in Non-Primary Joint After the Last Injection
Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, Within 30 days after last injection
Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection
Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
Time frame: Baseline, Day 30 after last injection
Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection
Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion
Time frame: Baseline, Day 30 after last injection
Time to Reach Clinical Success in Non-Primary Joint
Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
Time frame: Within 30 days after last injection
Clinical Success in Non-Primary Joint After the First Injection
Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after first injection
Clinical Improvement in Non-Primary Joint After the First Injection
Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, Within 30 days after first injection
Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection
Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
Time frame: Baseline, Day 30 after first injection
Change From Baseline Range of Motion in Non-Primary Joint After the First Injection
Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion
Time frame: Baseline, Day 30 after first injection
| Milestone | AA4500 0.58 mg | Placebo |
|---|---|---|
| Started | 45 | 21 |
| Completed | 45 | 19 |
| Not completed | 0 | 2 |
| Withdrew: Withdrew consent | 0 | 2 |
| Milestone | AA4500 0.58 mg | Placebo |
|---|---|---|
| Started | 64 | 0 |
| Completed | 58 | 0 |
| Not completed | 6 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 |
Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Reduction in Primary Joint Contracture to 5° or Less | 44.4 | 4.8 |
Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Improvement in Primary Joint After the Last Injection | 77.8 | 14.3 |
Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
| Percentage of change | AA4500 0.58 mg | Placebo |
|---|---|---|
| Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection | 70.5 ± 29.21 | 13.6 ± 26.10 |
Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion
| Degrees | AA4500 0.58 mg | Placebo |
|---|---|---|
| Change From Baseline Range of Motion in Primary Joint After the Last Injection | 35.4 ± 17.77 | 7.6 ± 14.88 |
Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Injection 1, Day 1 | 2.2 | 0.0 |
| Injection 1, Day 7 | 6.7 | 4.8 |
| Injection 1, Day 30 | 17.8 | 0.0 |
| Injection 2, Day 1 | 0.0 | 0.0 |
| Injection 2, Day 7 | 4.4 | 0.0 |
| Injection 2, Day 30 | 8.9 | 0.0 |
| Injection 3, Day 1 | 4.4 | 0.0 |
| Injection 3, Day 7 | 0.0 | 0.0 |
| Injection 3, Day 30 | 0.0 | 0.0 |
| Did not reach Clinical Success | 55.6 | 95.2 |
Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Success in Primary Joint After the First Injection | 26.7 | 4.8 |
Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Improvement in Primary Joint After the First Injection | 60.0 | 4.8 |
Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
| Percentage of change | AA4500 0.58 mg | Placebo |
|---|---|---|
| Percent Reduction From Baseline Contracture of Primary Joint After the First Injection | 58.5 ± 31.74 | 6.0 ± 20.79 |
Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion
| Degrees | AA4500 0.58 mg | Placebo |
|---|---|---|
| Change From Baseline Range of Motion in Primary Joint After the First Injection | 28.6 ± 17.41 | 3.6 ± 9.51 |
Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection | 53.9 |
Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement in Non-Primary Joint After the Last Injection | 70.8 |
Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
| Percentage of change | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection | 66.4 ± 34.63 |
Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion
| Degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection | 25.2 ± 16.80 |
Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Injection 1, Day 1 | 6.7 |
| Injection 1, Day 7 | 18.0 |
| Injection 1, Day 30 | 11.2 |
| Injection 2, Day 0 | 0.0 |
| Injection 2, Day 1 | 9.0 |
| Injection 2, Day 7 | 2.2 |
| Injection 2, Day 30 | 4.5 |
| Injection 3, Day 0 | 0.0 |
| Injection 3, Day 1 | 0.0 |
| Injection 3, Day 7 | 0.0 |
| Injection 3, Day 30 | 2.2 |
| Did not reach Clinical Success | 46.1 |
Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Clinical Success in Non-Primary Joint After the First Injection | 36.0 |
Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement in Non-Primary Joint After the First Injection | 58.4 |
Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
| Percentage of change | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection | 54.7 ± 38.37 |
Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion
| Degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion in Non-Primary Joint After the First Injection | 20.5 ± 17.52 |
Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.58 mg | — | 7/63 (11.1%) | 63/63 (100%) |
| Placebo | — | 1/21 (4.8%) | 10/21 (47.6%) |
| Event | AA4500 0.58 mg | Placebo |
|---|---|---|
| Inguinal hernia repairSocial circumstances | 0/63 | 1/21 |
| Abdominal hernia repairSurgical and medical procedures | 1/63 | 0/21 |
| Atrial fibrillationCardiac disorders | 1/63 | 0/21 |
| CholecystitisHepatobiliary disorders | 1/63 | 0/21 |
| Dupuytren's contractureMusculoskeletal and connective tissue disorders | 1/63 | 0/21 |
| Dupuytren's contracture operationSurgical and medical procedures | 1/63 | 0/21 |
| Ligament injuryInjury, poisoning and procedural complications | 1/63 | 0/21 |
| Orbital cystEye disorders | 1/63 | 0/21 |
| PneumoniaInfections and infestations | 1/63 | 0/21 |
| Sensory disturbanceNervous system disorders | 1/63 | 0/21 |
| Event | AA4500 0.58 mg | Placebo |
|---|---|---|
| Oedema peripheralGeneral disorders | 54/63 | 2/21 |
| ContusionInjury, poisoning and procedural complications | 46/63 | 2/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 36/63 | 3/21 |
| Injection site painGeneral disorders | 28/63 | 2/21 |
| Injection site haemorrhageGeneral disorders | 27/63 | 0/21 |
| Injection site swellingGeneral disorders | 23/63 | 3/21 |
| TendernessGeneral disorders | 20/63 | 0/21 |
| LymphadenopathyBlood and lymphatic system disorders | 13/63 | 0/21 |
| PruritusSkin and subcutaneous tissue disorders | 13/63 | 0/21 |
| Axillary painMusculoskeletal and connective tissue disorders | 8/63 | 0/21 |
| Age, Categorical(Participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 9 | 34 |
| >=65 years | 20 | 12 | 32 |
| Age, Continuous(years) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| Mean | 63.0 ± 7.8 | 65.5 ± 11.1 | 63.8 ± 9.0 |
| Sex: Female, Male(Participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 39 | 17 | 56 |
| Race/Ethnicity, Customized(participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| White | 45 | 21 | 66 |
| Region of Enrollment(participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| Australia | 45 | 21 | 66 |
Ran from Aug 2007 to primary completion in Sep 2008, 13 months.
Results were first posted in Oct 2010, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase